# Bob Soh

> Bob Soh is a Series A investor at Brandon Capital (Melbourne) backing Medical and Biopharma. See 2 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Brandon Capital](https://shizune.co/investors/profile/brandon-capital-partners)
- Location: Melbourne, Australia
- Total investments: 2
- Last investment: Jun 2020
- Lead investor: 100%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/bobsoh/
- Website: https://brandoncapital.vc/team_member/bob-soh/

Bob Soh is a Series A investor at Brandon Capital in Melbourne focused on Medical and Biopharma. Bob joined Brandon Capital in 2016. Before joining Brandon Capital, Bob worked at Nucleus Network, Australia’s largest clinical trials unit. He was an investigator in over 100 early-phase clinical trials, including as PI. He was heavily involved in various aspects of the business, including overseeing its clinical operations, business development,and expanding Nucleus Network’s trial capabilities.During his time at Nucleus Network, he was concurrently appointed as the acting CEO for Cardiora, a Brandon Capital investee company developing therapies for heart failure. He successfully led Cardiora through phase 2 clinical trials and successfully led the Company’s FDA regulatory and IP strategy. The program was subsequently licensed to a specialty pharmaceutical company.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 1 | 50% |
| Biopharma | 1 | 50% |
| Landscaping | 1 | 50% |
| Therapeutics | 1 | 50% |
| Biotechnology | 1 | 50% |

7 industries tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Glyscend Therapeutics | Glyscend develops a revolutionary approach to treating type 2 diabetes. The company began with the insight that bariatric surgery can lead to the immediate remission of the disease, and has since been engaged in the development of a non-invasive approach which will act on the same mechanism as surgery but fit within the current care pathway. Thecompany's technology is an orally ingestible intestinal coating that prevents the stimulation of duodenal mucosa and inhibits key neurohormonal pathways in the proximal gut. Glyscend is devoted to providing patients with an effective strategy to keep glucose levels under control and eliminate potential side effects like weight gain and hypoglycemia. Meanwhile, the company aims to provide endocrinologists and primary care physicians with the innovative tools they need to treat the disease instead of merely managing it. It was founded in 2014 by co-founders Ashish Nimgaonkar, Michael Parlato, and Pratik Patel. | $19.8M | Series A | Jun 11, 2020 |  |
| Glyscend Therapeutics | Glyscend develops a revolutionary approach to treating type 2 diabetes. The company began with the insight that bariatric surgery can lead to the immediate remission of the disease, and has since been engaged in the development of a non-invasive approach which will act on the same mechanism as surgery but fit within the current care pathway. Thecompany's technology is an orally ingestible intestinal coating that prevents the stimulation of duodenal mucosa and inhibits key neurohormonal pathways in the proximal gut. Glyscend is devoted to providing patients with an effective strategy to keep glucose levels under control and eliminate potential side effects like weight gain and hypoglycemia. Meanwhile, the company aims to provide endocrinologists and primary care physicians with the innovative tools they need to treat the disease instead of merely managing it. It was founded in 2014 by co-founders Ashish Nimgaonkar, Michael Parlato, and Pratik Patel. | $19.8M | Series A | Jun 11, 2020 |  |

2 of 2 investments shown.

## Co-investors
- [Sante Ventures](https://shizune.co/investors/profile/sante-ventures) — VC Fund, 2 deals together
- [Brandon Capital](https://shizune.co/investors/profile/brandon-capital-partners) — VC Fund, 1 deal together
- [Medical Research Commercialisation Fund (MRCF)](https://shizune.co/investors/profile/medical-research-commercialisation-fund-mrcf) — VC Fund, 1 deal together

## About Brandon Capital

VC Fund · Melbourne, Australia

Brandon Capital Partners is a funds management business aiming to generate quality returns for Australia's leading superannuation funds by investing in innovative life science ventures. Our team works with entrepreneurs to build businesses, creating value for the entrepreneurs, their teams and our investors.

5 contacts available at Brandon Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Chris Nave | Partner, Managing Director & Co-Founder | https://shizune.co/investors/profile/chris-nave |
| Robert Daniels | Venture Partner | https://shizune.co/investors/profile/robert-daniels |
| Stephen Thompson | Partner | https://shizune.co/investors/profile/stehpen-thompson |
| Bob Soh | Senior Investment Manager | https://shizune.co/investors/profile/bob-soh |
| Darren Kelly | Entrepreneur in Residence | https://shizune.co/investors/profile/darren-kelly-d974 |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Bob Soh invest in?

Bob Soh invests primarily in Medical, Biopharma and Landscaping startups, most often at Series A stage. Most of the 2 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Bob Soh last invest?

The most recent investment recorded for Bob Soh closed in Jun 2020. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co